There had been hopes that the trial could have had "far-reaching implications" for Alzheimer's patients

Alzheimer's patients have been dealt a blow after disappointing results from a major trial. Novo Nordisk has announced that trials of its Alzheimer’s treatment have not shown a “statistically significant” reduction in progression of the condition.

The firm has today announced the main results from a two-year primary analysis of so-called Evoke and Evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease. Evoke was testing semaglutide in people with early-stage Alzheimer's disease. Evoke+ was testing semaglutide but expanding to a broader population - allowing people who have extensive small blood vessel damage in the brain.

There had been huge expectation that the trials c

See Full Page